Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07211542
Recruiting Phase 2

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

NCT07211542 · tracked via the Priya Life Science China tracker
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase
Phase 2
Started
2025-11-07
Last updated
2026-04-08

Condition(s) studied

Moderate-to-severe Atopic Dermatitis

Investigational drug(s) / intervention(s)

SHR-1905 Injection →SHR-1905 Injection Blank Preparation

SHR-1905 Injection: SHR-1905 injection.

SHR-1905 Injection Blank Preparation: SHR-1905 injection blank preparation.

Study summary

This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. The subjects have voluntarily signed the informed consent form prior to the start of any procedures related to the study, are able to communicate smoothly with the researcher, understand and are willing to strictly abide by the requirements of this clinical research protocol to complete the study. 2. At the time of signing the informed consent, the subjects are ≥ 18 years old and ≤ 75 years old, male or female. 3. Have atopic dermatitis at screening. Exclusion Criteria: 1. Hypersensitivity to the study drug or any ingredient in the study drug. 2. Have other active skin disease or skin complications due to other conditions that may affect the evaluation of Atopic Dermatitis (AD). 3. Has malignancy or has a history of malignancy. 4. Have serious concomitant diseases and other conditions that the investigator considers inappropriate to participate in this trial. 5. Females who are pregnant or lactating.

Primary outcome measure(s)

  • The proportion of subjects whose Eczema Area and Severity Index (EASI) score decreased ≥ 75% compared to the baseline. — Week 16.
    Eczema Area and Severity Index (EASI) score using the Eczema Area and Severity Index scale.

Trial sites (1)

FacilityCityRegionStatus
Dermatology Hospital of Southern Medical University Guangzhou Guangdong Recruiting

More Guangdong Hengrui Pharmaceutical Co., Ltd trials in China

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia Recruiting
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis Recruiting
A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults Recruiting
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis Active, not recruiting
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors Active, not recruiting

Other trials for the same condition

A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis Starting soon
A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis Active, not recruiting
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07211542 on ClinicalTrials.gov ↗ ← All trials in China